{
    "Trade/Device Name(s)": [
        "Control-IQ Technology"
    ],
    "Submitter Information": "Tandem Diabetes Care, Inc.",
    "510(k) Number": "K200467",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QJI"
    ],
    "Summary Letter Date": "May 8, 2020",
    "Summary Letter Received Date": "May 11, 2020",
    "Submission Date": "February 20, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.1356"
    ],
    "Regulation Name(s)": [
        "Interoperable Automated Glycemic Controller"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ACE pump",
        "iCGM"
    ],
    "Method(s)/Technology(ies)": [
        "Automated glycemic control software"
    ],
    "Methodologies": [
        "Automated drug dose calculation",
        "Integrated device communication"
    ],
    "Submission Type(s)": [
        "Software",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Tandem Diabetes Care Control-IQ Technology interoperable automated glycemic controller software for insulin delivery management",
    "Indications for Use Summary": "Intended for use with compatible integrated continuous glucose monitors and alternate controller enabled pumps to automatically adjust insulin delivery for managing Type 1 diabetes mellitus in persons 6 years and older",
    "fda_folder": "Clinical Chemistry"
}